Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease

AIMS: Hyperkalaemia risk precludes optimal renin–angiotensin–aldosterone system inhibitor use in patients with heart failure (HF), particularly those with chronic kidney disease (CKD). Patiromer is a sodium‐free, non‐absorbed potassium (K(+))‐binding polymer approved for the treatment of hyperkalaem...

Descripción completa

Detalles Bibliográficos
Autores principales: Pitt, Bertram, Bushinsky, David A., Kitzman, Dalane W., Ruschitzka, Frank, Metra, Marco, Filippatos, Gerasimos, Rossignol, Patrick, Du Mond, Charles, Garza, Dahlia, Berman, Lance, Lainscak, Mitja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5933966/
https://www.ncbi.nlm.nih.gov/pubmed/29369537
http://dx.doi.org/10.1002/ehf2.12265

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5933966/
https://www.ncbi.nlm.nih.gov/pubmed/29369537
http://dx.doi.org/10.1002/ehf2.12265

Ejemplares similares